29 results
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
also affect patient recruitment or the ability of enrolled patients to complete any of our or our partners’ clinical trials or result in potential … to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability
F-1
EVAX
Evaxion Biotech A/S
12 Jan 24
Registration statement (foreign)
5:17pm
. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our or our partners’ clinical … could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we and/or our future partners
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
27 Apr 23
Fourth quarter and full year 2022 financial results and business update
8:30am
and interim Phase 2 data from the EVX-01 program in melanoma. In addition, we intend to initiate recruitment in a Phase 1 study with EVX-03 in Q4 2023. We … results from EVX-01 Phase 2 trial
Q4 2023 - Initiate patient recruitment in a Phase 1 study for EVX-03
Full Year 2022 Financial Results
Cash position
6-K
EX-99.2
oxiyi9e452zkoj
11 Aug 22
Current report (foreign)
4:30pm
6-K
vdfa2wj2n22
1 Jul 22
Current report (foreign)
5:09pm
6-K
EX-99.2
a31bov468z toy
12 May 22
Current report (foreign)
4:35pm
6-K
EX-99.1
nfkdyyi6q xfy
11 May 22
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
7:30am
6-K
EX-99.1
h6c2hgmkxlmnhkr5p x0
22 Mar 22
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
6:30am
6-K
EX-99.1
o4qwyyl0v6f2 6mol3kz
7 Mar 22
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
4:17pm
6-K
ylyju2h9f8ym
7 Mar 22
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
4:17pm
424B4
zs0 10wppbk5v2k
5 Nov 21
Prospectus supplement with pricing info
4:47pm
F-1/A
zaa7f
3 Nov 21
Registration statement (foreign) (amended)
7:50am
F-1
9fpqc
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.2
w5y8n5ft9udq12o96
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
DRS
s9b egwjped
25 Jun 21
Draft registration statement
12:00am
6-K
EX-99.1
xbezph ueglasnkj
13 May 21
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update
7:30am
20-F
plnpfgjmu ps
7 Apr 21
Annual report (foreign)
4:31pm